One-year clinical experience on the use of Nintedanib in systemic sclerosis

被引：0

作者：

Magnani, Luca ^{[1
]}

Spinella, Amelia ^{[2
]}

Testoni, Sofia ^{[1
,2
]}

Lumetti, Federica ^{[2
]}

Scelfo, Chiara ^{[3
]}

Dardani, Lucia ^{[1
]}

Bajocchi, Gianluigi ^{[1
]}

Clini, Enrico ^{[4
]}

Salvarani, Carlo ^{[1
,2
]}

Giuggioli, Dilia ^{[2
,5
]}

机构：

[1] AUSL IRCCS Reggio Emilia, Rheumatol Unit, Reggio Emilia, Italy

[2] Univ Modena & Reggio Emilia AOU Modena, Scleroderma Unit, Rheumatol, VIA POZZO 71, I-41100 Modena, Italy

[3] AUSL IRCSS Reggio Emilia, Pneumol Unit, Reggio Emilia, Italy

[4] Univ Modena & Reggio Emilia, Dept Med & Surg Sci Children & Adult, Resp Dis Unit, Pneumol, Reggio Emilia, Italy

[5] Univ Modena & Reggio E, Policlin Modena, Dept Med & Surg Sci Children & Adult, Rheumatol Unit, Via Pozzo 71, I-41100 Modena, Italy

来源：

RESPIROLOGY CASE REPORTS | 2023年 / 11卷 / 06期

关键词：

autoimmunity; fibrosis; interstitial lung disease; rare disease; systemic sclerosis; CLASSIFICATION; SCLERODERMA;

D O I：

10.1002/rcr2.1120

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

We reviewed 11 patients with systemic sclerosis-related ILD who were referred to our Scleroderma Unit from January 2020 to January 2021 and started Nintedanib. Non-specific interstitial pneumonia (NSIP) was prevalent (45%), usual interstitial pneumonia (UIP) and UIP/NSIP pattern were both 27%. Only one patient had a history of smoking. Eight patients were on mycophenolate mofetil (MMF), eight were treated with corticosteroids (mean dose 5 mg/day of Prednisone or equivalent), and three were on Rituximab. The mean modified British Council Medical Questionnaire (mmRC) decreased from 3 to 2.5. Two patients had to reduce their daily dose to 200 mg/day for severe diarrhoea. Nintedanib was generally well tolerated.

引用

页数：4

共 50 条

[21] Prevalence of peripheral eosinophilia and clinical associations in systemic sclerosis patients
Foocharoen, Chingching
Mahakkanukrauh, Ajanee
Maleewong, Pewpan
Maleewong, Wanchai
Jumnainsong, Amonrat
Pongkulkiat, Patnarin
Teawtrakul, Nattiya
Suwannaroj, Siraphop
Nanagara, Ratanavadee
AMERICAN JOURNAL OF THE MEDICAL SCIENCES, 2022, 363 (06) : 519 - 525
[22] Esophageal manometry in systemic sclerosis: findings and association with clinical manifestations
Markus, Juliana
Costa Pinto, Rogerio de Melo
Buso Matoso, Abadia Gilda
Ranza, Roberto
REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2020, 66 (01): : 48 - 54
[23] Anti-fibrotic nintedanib—a new opportunity for systemic sclerosis patients?
Ana Catarina Duarte
Maria José Santos
Ana Cordeiro
Clinical Rheumatology, 2018, 37 : 1123 - 1127
[24] TREATMENT WITH NINTEDANIB IN SYSTEMIC SCLEROSIS ASSOCIATED WITH INTERSTITIAL LUNG DISEASE: SAFETY AND EFFECTIVENESS AFTER ONE YEAR IN A REAL-LIFE COHORT
Corada, J.
Guillen-Del-Castillo, A.
Blazquez, I.
Codina, C.
Anton, A.
Mestre, J.
Gil, A.
Perurena-Prieto, J.
Ojanguren, I.
Villar, A.
Simeon Aznar, C. P.
ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1012 - 1013
[25] Nintedanib in the treatment of interstitial lung disease associated with systemic sclerosis: A justified hope?
Hachulla, E.
REVUE DE MEDECINE INTERNE, 2019, 40 (12): : 775 - 777
[26] Nintedanib inhibits fibroblast activation and ameliorates fibrosis in preclinical models of systemic sclerosis
Huang, Jingang
Beyer, Christian
Palumbo-Zerr, Katrin
Zhang, Yun
Ramming, Andreas
Distler, Alfiya
Gelse, Kolja
Distler, Oliver
Schett, Georg
Wollin, Lutz
Distler, Joerg H. W.
ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 (05) : 883 - 890
[27] Association of silica exposure with chest HRCT and clinical characteristics in systemic sclerosis
Ballerie, Alice
Cavalin, Catherine
Lederlin, Mathieu
Nicolas, Amelie
Garlantezec, Ronan
Jouneau, Stephane
Lecureur, Valerie
Cazalets, Claire
Belhomme, Nicolas
Paris, Christophe
Rosental, Paul-Andre
Jego, Patrick
Lescoat, Alain
SEMINARS IN ARTHRITIS AND RHEUMATISM, 2020, 50 (05) : 949 - 956
[28] An update on biomarker discovery and use in systemic sclerosis
Matsushita, Takashi
Takehara, Kazuhiko
EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2017, 17 (09) : 823 - 833
[29] The clinical relevance of sexual dysfunction in systemic sclerosis
Bruni, C.
Raja, J.
Denton, C. P.
Matucci-Cerinic, M.
AUTOIMMUNITY REVIEWS, 2015, 14 (12) : 1111 - 1115
[30] Effects of nintedanib in patients with limited cutaneous systemic sclerosis and interstitial lung disease
Allanore, Yannick
Khanna, Dinesh
Smith, Vanessa
Aringer, Martin
Hoffmann-Vold, Anna-Maria
Kuwana, MasatakaKuwana
Merkel, Peter A.
Stock, Christian
Sambevsk, Steven
Denton, Christopher P.
RHEUMATOLOGY, 2024, 63 (03) : 639 - 647

← 1 2 3 4 5 →